Zydus receives final approval from the USFDA for Tizanidine Tablets USP

Zydus Cadila has received the final approval from the USFDA to market Tizanidine Tablets USP in the strengths of 2 mg and 4 mg. The drug is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury and works by helping to relax the muscles. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. The group now has more than 180 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.